Role of Notch3 Signaling in Hypertensive Arteriopathy

Information

  • Research Project
  • 6769595
  • ApplicationId
    6769595
  • Core Project Number
    R01HL071649
  • Full Project Number
    7R01HL071649-02
  • Serial Number
    71649
  • FOA Number
  • Sub Project Id
  • Project Start Date
    7/1/2003 - 20 years ago
  • Project End Date
    3/31/2005 - 19 years ago
  • Program Officer Name
    LIN, MICHAEL
  • Budget Start Date
    6/29/2004 - 19 years ago
  • Budget End Date
    3/31/2005 - 19 years ago
  • Fiscal Year
    2004
  • Support Year
    2
  • Suffix
  • Award Notice Date
    6/29/2004 - 19 years ago

Role of Notch3 Signaling in Hypertensive Arteriopathy

DESCRIPTION (provided by applicant): The pathogenesis of hypertension-induced target organ damage is related to long-term changes in vessel function and structure determined by signaling pathways governing cell growth, programmed cell death, inflammation and matrix modulation. Within the spectrum of identified arteriopathies, CADASIL is a heritable syndrome of systemic small vessel disease predisposing to stroke and vascular dementia. The etiological basis for this syndrome is mutations within one of the Notch family of genes, Notch3. We have recently extended this clinical observation by studying hypertensive vessels and documenting the up-regulation of Notch3 expression in association with maladaptive vascular remodeling. Taken together, these clinical and animal model data support our central hypothesis that Notch3 is a major determinant of vascular structure. Although it is well established that the vascular complications of hypertension are associated with pathological hypertrophy and matrix deposition, the molecular basis of this phenomenon remains poorly defined. Our preliminary data provides provocative new links between the pathology of hypertensive arteriopathy, the putative mediator TGF-beta1 and the Notch3 transcriptional pathway. The proposed project will test the central hypothesis that Notch3 signaling is a critical determinant of maladaptive hypertensive vascular remodeling by up-regulating a key downstream molecular mediator of VSMC hypertrophy and matrix production--TGF-beta1-through the activation of an RBP-Jk- and HRT2-dependent transcriptional pathway. The hypothesis will be tested in vitro and in vivo by systematically implementing both a loss- and gain-of- function strategy, while addressing two fundamental questions: 1) What are the downstream determinants of hypertrophy and matrix production modulated by Notch3 in VSMC and 2) What is the biological significance of Notch3 signaling as a functional and structural determinant of maladaptive hypertensive vascular remodeling and target organ damage in vivo? Specifically, we will: Aim 1: Define the essential role of the Notch3-RBP-Jk--HRT2 signaling pathway as a determinant of TGF-beta1 expression in cultured VSMC. Aim 2: Determine the functional role of a gain of Notch3 signaling in promoting maladaptive vascular remodeling and target organ damage in the context of secondary hypertension in Notch3 transgenic mice. Aim 3: Determine the essential mediator role of Notch3 signaling in promoting maladaptive hypertensive vascular remodeling and target organ damage in the context of secondary hypertension in Notch3 null mice. Aim 4: Determine the essential mediator role of Notch3 signaling in promoting maladaptive hypertensive vascular remodeling and target organ damage in the context of genetic hypertension in Notch3 null mice. The successful completion of the aims of this proposal are anticipated to provide novel mechanistic insights into the determinants of maladaptive vascular remodeling that may have important clinical implications for preventing hypertension-induced target organ damage.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R01
  • Administering IC
    HL
  • Application Type
    7
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    307600
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:307600\
  • Funding Mechanism
  • Study Section
    ECS
  • Study Section Name
    Experimental Cardiovascular Sciences Study Section
  • Organization Name
    ADVANCED CARDIOVASCULAR SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SANTA CLARA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    95054
  • Organization District
    UNITED STATES